Emalex Biosciences

Emalex Biosciences is a private, clinical-stage biotech advancing ecopipam, a first-in-class D1 receptor antagonist, for Tourette syndrome. The company's Phase 3 trial met its primary and secondary endpoints, positioning it for a potential NDA submission and addressing a significant unmet need in a patient population with limited treatment options. With an active Expanded Access Program authorized by the FDA, Emalex is nearing a pivotal transition point towards commercialization. The company operates with a focused pipeline and a clear mission to alleviate the burden of tic disorders.

First-in-class selective dopamine D1 receptor antagonism.

The TS market has long been dominated by generic antipsychotics, but the recent approval of a novel drug (tebefenate) has changed the landscape. Ecopipam would compete as another novel agent, with its D1 mechanism being a key differentiator against both older D2 antagonists and the newer entrant.